Penile Cancer Treatment Market Size, Share, Growth, Trends and Forecast 2035

Penile Cancer Treatment Market Size & Forecast 2035

The global penile cancer treatment market was valued at US$2.71 billion in 2025 and is projected to reach US$4.67 billion by 2035, growing at a CAGR of 5.6% during 2026-2035. Market growth is supported by greater use of multimodal treatment, wider adoption of organ-preserving procedures, expansion of platinum-based chemotherapy, emerging checkpoint inhibitor combinations, genomic testing, and growing clinical research in advanced penile squamous cell carcinoma.

The treatment landscape is changing most rapidly in advanced disease. The HERCULES Phase II trial reported an objective response rate of 39.4% with pembrolizumab plus platinum-based chemotherapy, with median progression-free survival of 5.4 months and median overall survival of 9.6 months. The 2026 EAU-ASCO guidelines now include expanded discussion of immunotherapy, genomic testing, and molecularly selected treatment for advanced penile cancer.

Penile Cancer Treatment Market Highlights

• 2025 Market Size: US$2.71 Billion
• 2035 Market Size: US$4.67 Billion
• CAGR, 2026-2035: 5.6%
• Largest Region: North America
• Fastest-Growing Region: Asia-Pacific
• Largest Cancer Type: Squamous Cell Carcinoma, accounting for more than 95% of penile cancers
• Leading Systemic Treatment Segment: Chemotherapy
• Chemotherapy Market Share: 37.6% in the source-year treatment analysis
• Key Growth Areas: chemo-immunotherapy, organ-preserving surgery, HPV-directed therapeutics, PD-1/PD-L1 inhibitors, genomic profiling, molecularly selected therapy, improved lymph-node staging and centralised rare-cancer care.

Penile Cancer Treatment Market Overview

Penile cancer is a rare malignancy in high-income markets but carries a larger disease burden in parts of Asia, Latin America and Africa. Squamous cell carcinoma accounts for more than 95% of penile malignancies, making penile squamous cell carcinoma the central focus of clinical development and commercial treatment strategies.

GLOBOCAN 2024 recorded 34,765 new penile cancer cases and 12,346 deaths worldwide. Asia represented 52.2% of cases, followed by Europe at 19.9%, Latin America and the Caribbean at 13.6%, Africa at 7.5%, Northern America at 6.3%, and Oceania at 0.45%.

Localized penile cancer is still treated primarily with surgery, topical treatment, laser therapy or radiotherapy according to tumor stage and location. The 2026 EAU-ASCO guidelines emphasize organ preservation whenever oncological control can be maintained, reflecting the importance of preserving urinary and sexual function.

The commercial opportunity becomes more pharmaceutical-intensive as disease progresses to regional lymph nodes or distant metastatic sites. Platinum-based chemotherapy remains the preferred first-line systemic approach for distant metastatic disease, while immune checkpoint inhibitors, EGFR-directed therapy, and molecularly selected tumor-agnostic treatments are gaining clinical relevance.

White-Space Opportunities in the Penile Cancer Treatment Market

Chemo-Immunotherapy for Advanced Disease

Advanced penile cancer has historically had limited systemic treatment options and poor long-term outcomes. HERCULES provided prospective evidence for combining immune checkpoint inhibition with platinum chemotherapy.

Among 33 efficacy-evaluable patients, pembrolizumab plus platinum-based chemotherapy produced an objective response rate of 39.4%. One patient achieved a complete response, while 36.4% achieved a partial response. Median progression-free survival was 5.4 months, and median overall survival was 9.6 months.

The findings create room for larger confirmatory studies, biomarker development, and additional PD-1/PD-L1 combinations.

Perioperative Immunotherapy Could Expand Treatment Before Surgery

Immunotherapy development is moving into locally advanced but potentially resectable disease.

A prospective 2026 study evaluating sintilimab plus paclitaxel-cisplatin chemotherapy reported an objective response rate of 52.9% in the neoadjuvant cohort. Among patients with N2 or N3 penile squamous cell carcinoma, 71.4% remained progression-free at 18 months after their last clinical assessment.

The ongoing PRIAM Phase II study is also evaluating induction carboplatin/paclitaxel plus pembrolizumab before surgery in node-positive locally advanced penile squamous cell carcinoma. The study plans to enroll 50 patients.

Molecularly Selected Treatment Creates a Precision-Oncology Niche

The 2026 EAU-ASCO guidelines added a dedicated genomic-testing section and recognize that some patients with advanced penile cancer may qualify for tumor-agnostic therapies based on molecular features.

Molecularly selected options can include checkpoint inhibitors for mismatch-repair-deficient or high-tumor-mutational-burden cancers and HER2-directed treatment for eligible HER2-positive solid tumors in jurisdictions where tumor-agnostic indications are available.

Although actionable alterations remain uncommon, expanded genomic profiling creates new demand for next-generation sequencing, biomarker testing and referral to precision-oncology trials.

HPV-Associated Disease Creates New Therapeutic and Diagnostic Possibilities

HPV is involved in a substantial proportion of penile cancers. The EAU-ASCO guideline cites an overall HPV prevalence of 50.8% across 52 studies. HPV16 represented 68.3% of detected HPV genotypes in the cited analysis.

HPV-directed vaccines, therapeutic vaccines and adoptive T-cell approaches are therefore becoming relevant research areas for advanced disease. The growing role of p16 testing also supports more refined classification of HPV-associated and HPV-independent tumors.

High-Burden Emerging Markets Remain Underserved

More than half of global penile cancer cases occur in Asia, while Latin America and Africa together contribute another 21.1%. These markets carry a far higher share of global cases than of high-value oncology spending.

Improved access to urologic surgery, pathology, lymph-node staging, chemotherapy, and specialist oncology treatment could materially expand the treated population across India, Brazil, Southern Africa, and other high-burden markets.

Penile Cancer Treatment Market Key Takeaways

• The global penile cancer treatment market is projected to increase from US$2.71 billion in 2025 to US$4.67 billion by 2035, growing at a CAGR of 5.6% during 2026-2035.
• Squamous cell carcinoma represents more than 95% of penile cancers, making PSCC the core histological target for drug development, surgery, and clinical trials.
• Chemotherapy remains the leading systemic treatment segment, holding 37.6% of the treatment market in the source-year analysis, but immune checkpoint combinations are beginning to challenge a chemotherapy-only treatment model.
• North America remains the largest commercial market, while Asia-Pacific is the fastest-growing region. Asia also carries 52.2% of global penile cancer incidence, creating the largest underlying treatment population.
• HERCULES provides the strongest recent prospective signal for chemo-immunotherapy, with a 39.4% objective response rate in advanced penile squamous cell carcinoma.
• Genomic testing is becoming more relevant in advanced disease, with the 2026 EAU-ASCO guidelines introducing a dedicated genomic-testing section and recognizing molecularly selected treatment in suitable patients.
• Centralised treatment and international clinical collaboration will remain essential, as rare disease incidence limits patient recruitment and makes large randomized trials difficult to conduct within individual countries.

Penile Cancer Treatment Market Industry Trends and Strategic Insights

Organ Preservation Is Becoming More Important in Localized Disease

Modern penile cancer treatment seeks complete tumor removal while preserving as much penile tissue and function as possible. The 2026 EAU-ASCO guideline identifies penile preservation as the preferred approach for localized disease when oncological control is not compromised.

Patients with suitable PeIN, Ta, T1 and selected T2 lesions can receive organ-sparing surgery, topical treatment, laser procedures or radiotherapy depending on pathology and clinical characteristics.

This creates demand for specialist reconstructive surgery, pathology, brachytherapy and long-term surveillance.

Advanced Disease Is Moving Beyond Chemotherapy Alone

Platinum-based chemotherapy continues to anchor first-line systemic treatment. The EAU-ASCO guideline reports response rates of 50% with TIP in selected N2-N3 patients and 38.5% with TPF in prospective locally advanced or metastatic studies.

Checkpoint inhibition is creating a second therapeutic axis. HERCULES, PERICLES and ORPHEUS have provided prospective immune-oncology evidence, although efficacy varies substantially across regimens.

Immunotherapy Is Moving Into Combination Regimens

Single-agent checkpoint inhibitors have produced modest overall response rates in unselected advanced disease. PERICLES reported an ORR of 16.7% with atezolizumab-based treatment, while ORPHEUS reported an ORR of 16.7% with retifanlimab.

HERCULES increased the response rate to 39.4% using pembrolizumab with platinum-based chemotherapy, reinforcing the clinical rationale for combination rather than checkpoint-inhibitor monotherapy.

Genomic Testing Is Entering Clinical Decision-Making

The new genomic-testing section in the 2026 EAU-ASCO guidelines reflects growing interest in molecular stratification. Genomic testing may help identify rare patients eligible for tumor-agnostic treatments and can support clinical-trial matching.

The market opportunity includes NGS panels, p16 testing, mismatch repair analysis, tumor mutational burden assessment and emerging HER2 testing.

HPV Status Is Becoming More Clinically Relevant

The 2026 guideline recommends p16 assessment as part of pathological evaluation. p16 acts as a surrogate marker for oncogenic HPV activity and can help classify tumors into HPV-associated and HPV-independent groups.

This classification may become increasingly valuable as HPV-directed therapeutic approaches enter clinical development.

Rare-Cancer Care Is Becoming More Centralised

Penile cancer management requires expertise in urologic oncology, reconstructive surgery, pathology, medical oncology, radiation oncology and lymph-node management.

The 2026 EAU-ASCO guideline includes expanded discussion of the advantages of centralised care, reflecting the need to concentrate experience and improve adherence to treatment standards in a disease with low case volumes per institution.

Penile Cancer Treatment Market Scope

Penile Cancer Treatment Market Disruption Analysis

HERCULES Changes the Advanced-Disease Development Benchmark

Advanced penile cancer has lacked major systemic-treatment breakthroughs for decades. HERCULES is important because it prospectively evaluated checkpoint inhibition combined with standard chemotherapy in a dedicated penile cancer population.

The trial enrolled 37 patients at 11 Brazilian centers. Among the 33 efficacy-evaluable patients, objective response reached 39.4%, while tumor shrinkage of any magnitude occurred in 75.8%.

Future systemic therapies will increasingly be compared with chemo-immunotherapy rather than chemotherapy alone.

Perioperative Immunotherapy Could Change Surgery Sequencing

Current studies are testing whether immunotherapy before surgery can shrink bulky nodal disease and increase the number of patients who can undergo curative-intent resection.

PRIAM is assessing carboplatin/paclitaxel plus pembrolizumab in node-positive locally advanced disease, while a prospective 2026 study of sintilimab plus chemotherapy reported a 52.9% neoadjuvant response rate.

These programs could shift part of the market toward planned systemic treatment before surgery.

Molecular Selection Creates Paths Beyond Histology

The 2026 EAU-ASCO guideline recognizes molecularly selected treatment for eligible patients when appropriate tumor-agnostic indications are available.

This introduces a treatment model in which a rare penile cancer can become eligible for a therapy because of MSI, mismatch repair, TMB or HER2 characteristics rather than penile origin alone.

Legacy Drug Approvals Do Not Reflect Modern Treatment Strategy

NCI's penile cancer drug page specifically lists bleomycin sulfate as an FDA-approved drug for penile cancer. However, the 2026 EAU-ASCO guideline recommends against bleomycin in advanced disease because of pulmonary toxicity risk.

This gap between older regulatory history and modern clinical practice highlights how much of the current market depends on multimodal treatment, off-label oncology regimens and clinical trials rather than recently approved penile cancer-specific drugs.

Penile Cancer Treatment Market Dynamics

Driver: Persistent Global Disease Burden

GLOBOCAN 2024 recorded 34,765 new penile cancer cases worldwide, with 12,346 deaths. Asia carried the largest incidence burden with 18,160 cases, followed by Europe with 6,919 and Latin America and the Caribbean with 4,740.

The disease remains rare globally, but the concentration of cases in specific countries and regions creates meaningful specialist-treatment demand.

Driver: Expansion of Multimodal Therapy

Penile cancer increasingly requires combinations of surgery, lymph-node dissection, chemotherapy and radiotherapy in patients with nodal or locally advanced disease.

For clinical N3 disease, neoadjuvant chemotherapy has produced pooled radiologic response rates of 53% and pathological complete response rates of 12.8% across available studies.

Patients who respond and subsequently undergo surgical consolidation represent the group with the strongest long-term outcomes.

Driver: Growing Immunotherapy Evidence

HERCULES demonstrated an ORR of 39.4% with pembrolizumab plus platinum chemotherapy. The 2026 EAU-ASCO guidelines now discuss HERCULES alongside PERICLES, ORPHEUS and immune-oncology basket studies.

This creates a larger development opportunity for checkpoint inhibitors and immunotherapy combinations.

Driver: HPV-Associated Biology

HPV is involved in one-third to one-half of penile cancers, and an analysis cited by EAU-ASCO found HPV DNA in 50.8% of cases.

This supports continued research into HPV-directed immunotherapy, therapeutic vaccines and improved biomarker classification.

Driver: Better Lymph-Node Staging

Nodal involvement is one of the strongest determinants of prognosis. EAU data report five-year cancer-specific survival of 95% for N0 disease, 80% for N1, 65% for N2 and 35% for N3.

Better use of dynamic sentinel-node biopsy, ultrasound-guided sampling, PET/CT and structured nodal surgery can improve staging accuracy and identify patients who need systemic treatment earlier.

Restraint: Rare Disease Limits Clinical-Trial Recruitment

Only 34,765 cases were recorded globally in 2024, and individual specialist centers often see relatively small patient numbers.

Low recruitment makes randomized studies difficult and increases reliance on single-arm Phase II studies, registries, basket trials and international collaborations.

Restraint: Advanced Disease Still Has Poor Survival

Advanced penile cancer remains difficult to treat. In HERCULES, median overall survival was 9.6 months despite the addition of pembrolizumab to chemotherapy.

EAU-ASCO also notes that effective second-line chemotherapy is lacking and that median overall survival after second-line treatment has remained six months or less in several studies.

Restraint: Treatment-Related Morbidity

Radical penile surgery and inguinal lymph-node dissection can significantly affect sexual function, urination, body image, and quality of life.

The need to balance cancer control with functional preservation is one of the reasons organ-preserving surgery, reconstructive techniques and centralized specialist care are increasingly important.

Penile Cancer Treatment Market Segment Analysis

By Cancer Type

Squamous Cell Carcinoma Dominates the Penile Cancer Treatment Market

Squamous cell carcinoma accounts for more than 95% of penile cancers, making it the dominant cancer-type segment by a wide margin.

The commercial importance of PSCC extends across every major treatment category. Localized disease can require organ-sparing surgery, topical treatment, laser ablation or radiation, while node-positive and metastatic PSCC account for most systemic chemotherapy and immunotherapy use.

The 2025 HERCULES study, 2026 sintilimab perioperative study, and ongoing PRIAM program all specifically focus on penile squamous cell carcinoma, reinforcing its dominance in pharmaceutical research.

Adenocarcinoma, basal cell carcinoma, melanoma, sarcoma, and other penile malignancies collectively account for less than 5% of cases. Their rarity limits dedicated drug development and generally requires individualized treatment based on histology and tumor biology.

By Treatment

Chemotherapy Holds the Largest Established Systemic Treatment Share

Chemotherapy held 37.6% of the penile cancer treatment market in the source-year analysis, making it the leading treatment segment in the existing market structure.

Platinum-based regimens remain central in regionally advanced and metastatic disease. Current EAU-ASCO recommendations identify platinum chemotherapy as the preferred first-line systemic treatment for distant metastatic penile cancer. Regimens include cisplatin/fluorouracil, TIP, TPF, and platinum-taxane combinations depending on patient fitness and treatment setting.

Chemotherapy's market position is changing as checkpoint inhibitors are increasingly incorporated into combination regimens rather than used only after chemotherapy failure.

Surgery Remains the Core Localized-Disease Treatment

Surgery remains the most important treatment for localized penile cancer. The modern clinical direction favors preserving as much penile tissue as possible without compromising tumor control.

Treatment can include circumcision, wide local excision, glans resurfacing, glansectomy, partial penectomy or total penectomy depending on tumor depth and location. Lymph-node surgery becomes critical in patients with regional nodal disease.

The surgical segment is increasingly influenced by reconstructive techniques, sentinel-node procedures and centralized high-volume care.

Immunotherapy Is the Fastest-Evolving Systemic Segment

Immune checkpoint inhibitors remain a developing rather than universally established penile-specific treatment class, but evidence is expanding.

HERCULES produced a 39.4% ORR with pembrolizumab plus chemotherapy. PERICLES reported a 16.7% ORR with atezolizumab-based treatment, while ORPHEUS reported a 16.7% ORR with retifanlimab.

The segment is expected to gain strategic importance as perioperative studies, molecular-selection strategies and HPV-directed approaches mature.

Radiation Therapy Remains Important for Selected Localized and Advanced Disease

Radiation can be used as organ-preserving treatment for selected T1 and T2 lesions, as part of multimodal management of locally advanced disease and for palliation in metastatic cancer.

The InPACT program is also standardizing radiation planning and treatment across participating centers, which could improve consistency in future clinical evidence.

Topical Therapy Serves Early and Pre-Invasive Disease

Topical fluorouracil and imiquimod can be used in selected stage 0 disease and penile intraepithelial neoplasia. These treatments preserve anatomy and can avoid more extensive surgery when disease remains superficial.

By Disease Setting

Localized disease represents the largest treatment population and generates demand for urologic surgery, organ-preserving procedures, pathology, and surveillance.

Regionally advanced disease accounts for a smaller patient population but substantially greater treatment intensity because management can combine chemotherapy, extensive lymph-node surgery and radiotherapy.

Metastatic disease represents the smallest patient segment but creates the strongest unmet need for new systemic therapies. HERCULES reported that 64.9% of its enrolled patients had metastatic disease, demonstrating how advanced clinical trials concentrate on patients with limited standard alternatives.

By End User

Hospitals and specialist cancer centers account for the largest treatment activity because penile cancer frequently requires multidisciplinary management involving urologists, reconstructive surgeons, pathologists, radiologists, radiation oncologists, and medical oncologists.

Specialty urology centers play an important role in localized disease, surveillance, and penile-preserving procedures. Academic cancer centers carry greater importance in advanced disease because clinical-trial access is particularly relevant when patients progress after platinum chemotherapy.

The movement toward centralized treatment is likely to strengthen the role of specialist referral centers through 2035.

Penile Cancer Treatment Market Regional Analysis

North America

North America remains the largest commercial penile cancer treatment market, with the existing market analysis placing the region at one-third of global market revenue.

The region's commercial leadership contrasts with its disease-burden share. North America recorded 2,193 new cases in 2024, representing 6.3% of global incidence.

The United States drives regional revenue through high treatment expenditure, specialized urologic oncology, access to complex surgery, molecular testing, and participation in early-phase immunotherapy studies.

North America's market is expected to retain high revenue per patient as treatment becomes more biomarker-driven and advanced systemic regimens incorporate checkpoint inhibitors.

Asia-Pacific

Asia-Pacific is the fastest-growing commercial region and has the largest underlying penile cancer population.

Asia recorded 18,160 new penile cancer cases in 2024, representing 52.2% of global incidence.

India alone recorded 7,169 cases in 2024, giving the country more than one-fifth of the worldwide case burden.

Growth opportunities are tied to wider specialist urology access, better pathology, lymph-node staging, oncology infrastructure and increasing participation in immunotherapy and rare-cancer research. Chinese investigators are also contributing to perioperative checkpoint-inhibitor development, including studies of sintilimab and toripalimab-based treatment.

Europe

Europe recorded 6,919 new penile cancer cases in 2024, accounting for 19.9% of global incidence.

The region has a well-developed network of specialist cancer centers and plays a major role in establishing international treatment guidelines. The EAU-ASCO penile cancer guideline underwent a major update in 2026, including new genomic-testing guidance, revised systemic-treatment pathways and expanded recommendations on centralised care.

European clinical research is also important. The Netherlands Cancer Institute is sponsoring the PRIAM trial of pembrolizumab plus chemotherapy in locally advanced disease, while InPACT includes international efforts to improve multimodal management and radiation standardization.

Latin America

Latin America and the Caribbean recorded 4,740 penile cancer cases in 2024, representing 13.6% of global incidence.

The region has a much larger disease burden relative to its population than North America. Brazil is a major contributor and recorded 1,596 new penile cancer cases and 570 deaths in 2024.

Brazil is also emerging as an important clinical-research center. HERCULES enrolled patients across 11 Brazilian centers and provided one of the strongest recent prospective datasets for advanced penile cancer treatment.

This combination of disease burden and growing clinical research makes Brazil a strategically important market for chemo-immunotherapy development.

Middle East and Africa

Africa recorded 2,596 new penile cancer cases in 2024, representing 7.5% of global incidence.

The disease burden is unevenly distributed. Southern Africa has some of the world's highest incidence rates, and GLOBOCAN 2024 identifies Botswana with an age-standardized penile cancer incidence rate of 8.1 per 100,000 males.

Treatment access remains concentrated in tertiary hospitals. Greater availability of urologic surgery, pathology, radiotherapy and systemic oncology treatment represents a major unmet need.

Middle Eastern markets generally have lower incidence than Southern Africa but include high-spending specialist healthcare systems capable of adopting modern molecular testing and oncology treatment.

Penile Cancer Treatment Country-Level Analysis

India

India represents the largest clearly identified country-level penile cancer burden in the current GLOBOCAN 2024 dataset reviewed for this analysis.

The country recorded 7,169 new penile cancer cases and 2,578 deaths in 2024. This equals 20.6% of global penile cancer cases. Five-year prevalence reached 17,343 patients.

India's large patient population creates demand for early diagnosis, penile-preserving surgery, lymph-node management and affordable systemic treatment. Expansion of specialist oncology centers could materially increase the treated population through 2035.

United States

The American Cancer Society projects 2,260 new penile cancer cases and 450 deaths in the United States in 2026.

The U.S. represents a high-value market despite relatively low incidence because patients have access to specialist surgery, radiotherapy, genomic testing, and clinical trials.

The country is also commercially important for tumor-agnostic oncology drugs that can become relevant to molecularly selected patients with advanced penile cancer.

Brazil

Brazil recorded 1,596 new cases and 570 deaths from penile cancer in 2024, with a five-year prevalence of 4,523 patients.

The country combines high disease burden with strong academic oncology research. HERCULES recruited across Brazilian centers and demonstrated a 39.4% response rate with pembrolizumab plus platinum-based chemotherapy.

Brazil is therefore both a treatment market and an important clinical-development location for advanced penile cancer.

United Kingdom

The United Kingdom records around 820 new penile cancer cases each year, with Cancer Research UK reporting 871 new cases across its most recent combined annual dataset. Incidence rates have risen by 20% over the last decade covered by the data.

The UK's centralized specialist-care model supports advanced penile-preserving surgery and multidisciplinary treatment. Increasing incidence also raises the importance of early recognition and referral.

Spain

Spain recorded 522 new penile cancer cases and 129 deaths in 2024, with five-year prevalence reaching 1,762 patients.

Spain benefits from established oncology and urology infrastructure and access to European treatment guidelines, making it relevant for specialist surgical treatment, radiotherapy, and systemic oncology care.

Penile Cancer Treatment Market Epidemiology and Biomarker Analysis

The latest GLOBOCAN dataset records 34,765 new cases and 12,346 deaths worldwide in 2024. Asia contributes more than half of global incidence, while Europe and Latin America together account for another 33.5%.

Histologically, penile cancer is highly concentrated. More than 95% of penile cancers are squamous cell carcinomas, while melanoma, basal cell carcinoma, sarcoma, and other histologies represent a small minority.

HPV biology divides PSCC into clinically important molecular groups. The overall HPV prevalence reported across 52 studies is 50.8%, while p16 immunohistochemistry positivity has been reported in 41.6% of penile cancers.

HPV-associated tumors can differ from HPV-independent tumors in histology, molecular characteristics, and prognosis. The EAU-ASCO guideline recommends including p16 assessment in pathological evaluation, strengthening the role of biomarker-based classification.

Nodal status remains one of the strongest prognostic factors. Five-year cancer-specific survival falls from 95% in N0 disease to 80% in N1, 65% in N2, and 35% in N3 disease.

These differences make early lymph-node staging and rapid treatment of nodal disease critical to outcomes.

Penile Cancer Treatment Market Pipeline Analysis

Pembrolizumab Plus Chemotherapy

HERCULES has created a clinical foundation for pembrolizumab-based chemo-immunotherapy in advanced disease.

The Phase II study reported a 39.4% objective response rate, median PFS of 5.4 months and median OS of 9.6 months. PD-L1 CPS ≥1 was present in 78.4% of enrolled patients, while 10.8% had TMB-high tumors.

These biomarker data support additional research into which patients derive the greatest benefit from checkpoint inhibition.

PRIAM

The PRIAM Phase II trial is evaluating carboplatin/paclitaxel plus pembrolizumab as induction treatment for node-positive locally advanced penile squamous cell carcinoma.

The study plans to recruit 50 patients and uses pathological complete response as a primary efficacy endpoint. It will also evaluate PD-L1, high-risk HPV, progression-free survival and overall survival.

Sintilimab Plus Chemotherapy

A prospective 2026 study of perioperative sintilimab plus paclitaxel and cisplatin reported a 52.9% objective response rate in evaluable neoadjuvant patients.

The results support further investigation of PD-1 inhibition in resectable but locally advanced penile cancer.

Toripalimab and EGFR Combination Strategy

EAU-ASCO cites a Phase II Chinese study evaluating toripalimab, the EGFR-directed antibody nimotuzumab and triplet chemotherapy before surgery.

Among 24 patients who underwent consolidative surgery, 14 achieved a pathological complete response. Two-year overall survival was 72.4% and progression-free survival was 65.5%.

The multi-agent design makes it difficult to determine the contribution of each component, but the response rates justify continued investigation.

EGFR-Directed Treatment

EGFR remains one of the more established targeted-treatment research pathways in PSCC.

EAU-ASCO reports that dacomitinib produced an objective response rate of 32.1% in 28 patients, including one complete response.

Future targeted-treatment development will need to identify biomarkers that can better select patients likely to respond.

InPACT

The International Penile Advanced Cancer Trial is evaluating the sequencing of chemotherapy, chemoradiotherapy and lymph-node surgery in locally advanced disease.

The program has also produced standardized radiation-therapy guidance for inguinal and pelvic lymph nodes, helping create consistent treatment protocols across participating centers.

Penile Cancer Treatment Market Company Positioning

Merck & Co.

Merck has the strongest emerging immune-oncology position through KEYTRUDA (pembrolizumab).

Pembrolizumab plus chemotherapy achieved a 39.4% response rate in HERCULES, while PRIAM is evaluating pembrolizumab with carboplatin and paclitaxel before surgery in locally advanced disease.

Pembrolizumab can also have relevance through tumor-agnostic indications in molecularly selected patients.

Bristol Myers Squibb

Bristol Myers Squibb participates in the emerging immunotherapy landscape through nivolumab and ipilimumab.

EAU-ASCO cites a Phase I-II basket study in which nine penile SCC patients received nivolumab with cabozantinib, with or without ipilimumab. Four patients achieved partial responses and five had stable disease.

Roche

Roche's atezolizumab was evaluated in the PERICLES trial for advanced penile cancer.

The study reported a confirmed response rate of 16.7% and median overall survival of 11.3 months.

While the response rate was modest, the study contributed important prospective evidence for checkpoint inhibition in this rare tumor.

Incyte

Incyte participates through retifanlimab, evaluated in the ORPHEUS study.

The trial included 18 patients and reported an objective response rate of 16.7%, median progression-free survival of 2.0 months and median overall survival of 7.2 months.

Innovent Biologics

Innovent's sintilimab is being studied as part of perioperative chemo-immunotherapy for locally advanced penile squamous cell carcinoma.

The 2026 prospective study reported a 52.9% neoadjuvant response rate, supporting continued clinical interest in PD-1 inhibition before surgery.

Shanghai Junshi Biosciences

Junshi's toripalimab is part of an investigational multimodal strategy combining PD-1 inhibition, EGFR targeting and chemotherapy before surgery.

The Phase II regimen generated high pathological response rates and two-year survival signals in locally advanced PSCC.

Additional Oncology Participants

Other companies with potential strategic relevance include GSK through molecularly selected checkpoint inhibition, AstraZeneca and Daiichi Sankyo through tumor-agnostic HER2-directed therapy, and companies developing HPV-directed vaccines, T-cell therapies or EGFR-targeting agents.

The commercial landscape remains fragmented because most emerging treatments are used through trials, tumor-agnostic indications or extrapolation from other squamous-cell carcinomas rather than dedicated penile cancer approvals.

Penile Cancer Treatment Market Competitive Landscape

Penile cancer remains one of the least commercially consolidated oncology treatment markets. Competition is distributed across platinum chemotherapy, immune checkpoint inhibition, EGFR-targeted treatment, tumor-agnostic precision oncology, surgery and radiotherapy.

Chemotherapy remains the established systemic leader, but immune-oncology is becoming the principal pharmaceutical innovation area. Merck has gained clinical visibility through HERCULES and PRIAM, while Bristol Myers Squibb, Roche, Incyte, Innovent and Shanghai Junshi have generated additional checkpoint-inhibitor data.

The next competitive transition is likely to depend on perioperative treatment. A therapy capable of converting bulky node-positive disease into resectable disease, increasing pathological complete response and improving long-term survival would occupy a high-value treatment position.

Molecular stratification will create smaller commercial niches around MSI-H/dMMR, TMB-high, HER2-positive and other actionable tumors. Because these biomarker-defined groups are uncommon, global trial networks and centralized diagnostic testing will remain essential.

Penile Cancer Treatment Market Key Developments

2026: EAU-ASCO Penile Cancer Guidelines Receive Major Update

The 2026 EAU-ASCO guidelines introduce a dedicated genomic-testing section, restructure immunotherapy guidance, update systemic and palliative treatment pathways and expand recommendations on centralised care.

2026: Perioperative Sintilimab Study Reports Clinical Activity

A prospective study of sintilimab with paclitaxel-cisplatin chemotherapy reported an objective response rate of 52.9% in the neoadjuvant cohort. Among enrolled N2 or N3 patients, 71.4% remained progression-free at 18 months after their final clinical assessment.

2025: HERCULES Published in JAMA Oncology

HERCULES was published in September 2025 and reported an objective response rate of 39.4%, median PFS of 5.4 months, and median OS of 9.6 months with pembrolizumab plus platinum-based chemotherapy.

2025: InPACT Establishes International Radiation Standards

The InPACT program published international consensus guidance for radiotherapy to inguinal and pelvic lymph nodes in locally advanced penile cancer. Trial recruitment remained ongoing, with survival and toxicity outcomes to follow.

2025-2026: PRIAM Continues Recruitment

The Netherlands Cancer Institute's PRIAM Phase II study continues to assess induction carboplatin/paclitaxel plus pembrolizumab before surgery in locally advanced node-positive penile cancer.

Key Procurement Priorities and Buyer Evaluation Criteria

Healthcare systems treating penile cancer need to evaluate the entire care pathway rather than drug acquisition cost alone.

• Treatment setting and stage are the first considerations. Localized disease can often be managed with organ-preserving procedures, while node-positive and metastatic disease require more complex multidisciplinary treatment.
• Pathology quality is critical. Histological subtype, grade, lymphovascular invasion, depth of invasion and p16 status influence prognosis and subsequent treatment decisions. The 2026 EAU-ASCO guideline recommends p16 assessment in pathological evaluation.
• Lymph-node staging capacity affects outcomes. Dynamic sentinel-node biopsy, ultrasound-guided sampling, and specialist lymphadenectomy determine whether occult nodal disease is identified early.
• Systemic-treatment procurement requires toxicity management. Platinum and taxane combinations can produce significant hematologic, neurologic, and renal toxicity, while immune checkpoint inhibitors introduce immune-mediated adverse events.
• Clinical-trial access is a strategic consideration. EAU-ASCO strongly recommends clinical-trial participation for advanced penile squamous cell carcinoma whenever suitable trials are available.
• Genomic testing is becoming more valuable. Advanced cancer centers increasingly require access to mismatch-repair testing, TMB assessment, HER2 testing, and NGS to identify uncommon but actionable molecular subsets.
• Quality of life and organ preservation remain central. Buyers and providers must consider urinary function, sexual function, reconstructive requirements, and long-term psychological impact alongside cancer control.